Catheter

Shockwave Medical Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 7, 2023

SANTA CLARA, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended June 30, 2023.

Key Points: 
  • SANTA CLARA, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended June 30, 2023.
  • Gross profit for the second quarter of 2023 was $155.7 million compared to $104.0 million for the second quarter of 2022.
  • Total operating expenses for the second quarter of 2023 were $123.3 million, a 66% increase from $74.4 million in the second quarter of 2022.
  • Shockwave Medical will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on Monday, August 7, 2023, to discuss its second quarter 2023 financial results.

Asep Inc. Obtains Exclusive Worldwide License from the University of British Columbia for Ground-breaking Medical Device Coating Technology

Retrieved on: 
Wednesday, August 2, 2023

Catheters are an excellent example of medical instruments that can cause serious infections.

Key Points: 
  • Catheters are an excellent example of medical instruments that can cause serious infections.
  • According to the Center for Disease Control and Prevention (CDC), approximately 90% of serious infections caused by catheters are associated with central venous catheters (CVCs).
  • UBC and the non-waiving inventors of the Technology will collectively own the remaining 12% of the issued and outstanding shares of SafeCoat in consideration for the exclusive license grant.
  • Dr. Robert E. W. Hancock, Founder and CEO of Asep Inc., is one of the four non-waiving inventors of the SafeCoat Technology.

Asep Inc. Obtains Exclusive Worldwide License from the University of British Columbia for Ground-breaking Medical Device Coating Technology

Retrieved on: 
Tuesday, August 1, 2023

Catheters are an excellent example of medical instruments that can cause serious infections.

Key Points: 
  • Catheters are an excellent example of medical instruments that can cause serious infections.
  • According to the Center for Disease Control and Prevention (CDC), approximately 90% of serious infections caused by catheters are associated with central venous catheters (CVCs).
  • UBC and the non-waiving inventors of the Technology will collectively own the remaining 12% of the issued and outstanding shares of SafeCoat in consideration for the exclusive license grant.
  • Dr. Robert E. W. Hancock, Founder and CEO of Asep Inc., is one of the four non-waiving inventors of the SafeCoat Technology.

Microbot Medical Engaging with a Leading Notified Body to Advance CE Mark for Sales in Europe

Retrieved on: 
Tuesday, July 25, 2023

HINGHAM, Mass., July 25, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, today announced the first steps towards its planned European market clearance, by engaging with a leading Notified Body.

Key Points: 
  • HINGHAM, Mass., July 25, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, today announced the first steps towards its planned European market clearance, by engaging with a leading Notified Body.
  • The Notified Body will audit the Company to verify the compliance of its quality management system and the quality of the LIBERTY Robotic Surgical System development with widely acceptable standards in the medical device industry.
  • In addition, preparations are being made to obtain EU-MDR certification (European Medical Devices Regulation) leading to CE mark, which would allow the Company to sell the LIBERTY Robotic Surgical System throughout the European Union.
  • “Following the success of multiple pre-clinical studies conducted with the participation of leading European-based interventional radiologists, Microbot is now expanding to seek a wider range of potential users in key growth markets,” commented Harel Gadot, Chairman, President and CEO.

Unsolicited Diabetes Supplies: The New York StateWide Senior Action Council's "Medicare Fraud of the Month" for July

Retrieved on: 
Thursday, July 20, 2023

The StateWide Fraud of the Month is a component of the Senior Medicare Patrol, the definitive resource for New York State's senior citizens and caregivers to detect, prevent, and report healthcare fraud, errors, and abuse.

Key Points: 
  • The StateWide Fraud of the Month is a component of the Senior Medicare Patrol, the definitive resource for New York State's senior citizens and caregivers to detect, prevent, and report healthcare fraud, errors, and abuse.
  • "Senior Medicare Patrols across the country report diabetic supply charges found on Medicare statements when the beneficiary doesn't have diabetes," announced Maria Alvarez, Executive Director of the New York StateWide Senior Action Council.
  • The NYS Senior Medicare Patrol has a hotline for people who believe they have been a victim of any Medicare fraud.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/unsolicited-diabetes-supplies-t...
    SOURCE New York StateWide Senior Action Council, Inc.

Ivy Brain Tumor Center Opens Novel Clinical Trial to Test Direct-to-Tumor Drug Delivery Method

Retrieved on: 
Tuesday, July 18, 2023

SSIAI is a novel technique that can deliver a highly-concentrated dose of experimental drug directly to the brain tumor while minimizing systemic side effects.

Key Points: 
  • SSIAI is a novel technique that can deliver a highly-concentrated dose of experimental drug directly to the brain tumor while minimizing systemic side effects.
  • “Drug delivery is arguably the most significant problem in brain tumor treatment today,”  says Nader Sanai, MD, Director of the Ivy Brain Tumor Center and Director of Neurosurgical Oncology at Barrow Neurological Institute.
  • Additional clinical trial information can be found at NCT05773326 or the Ivy Brain Tumor Center’s website .
  • The Ivy Brain Tumor Center at Barrow Neurological Institute facilitates the largest early-phase drug development program for brain cancer.

ŌNŌCOR signs an exclusive US distribution agreement with B. Braun Interventional Systems

Retrieved on: 
Monday, July 17, 2023

PHILADELPHIA, July 17, 2023 (GLOBE NEWSWIRE) -- ŌNŌCOR LLC , a medical technology company dedicated to developing essential safety tools and other facilitating technologies for the modern-day catheterization lab, today announced that they have signed an exclusive distribution agreement with B. Braun Interventional Systems Inc .

Key Points: 
  • PHILADELPHIA, July 17, 2023 (GLOBE NEWSWIRE) -- ŌNŌCOR LLC , a medical technology company dedicated to developing essential safety tools and other facilitating technologies for the modern-day catheterization lab, today announced that they have signed an exclusive distribution agreement with B. Braun Interventional Systems Inc .
  • (BIS) as an important next step in preparation for the commercial launch of the ŌNŌ Retrieval Device in the US.
  • Under the agreement, BIS will initiate the US commercialization activities for ŌNŌCOR’s ŌNŌ Retrieval Device.
  • The ŌNŌ is a novel device designed to receive, align, compress and remove material (non-biologic and biologic) from the vascular system.

Global General Surgery Devices Market Trends/Analysis Report 2023: A $29.9 Billion Market by 2030 Fueled by Increased Number of Procedures and Patient Affordability - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 13, 2023

The global general surgery devices market size is expected to reach USD 29.9 billion by 2030, registering a CAGR of 8.39%

Key Points: 
  • The global general surgery devices market size is expected to reach USD 29.9 billion by 2030, registering a CAGR of 8.39%
    The global general surgery devices market is projected to reach a substantial size of USD 29.9 billion by 2030, with a strong CAGR of 8.39%.
  • Investing in this market presents an opportunity to capitalize on the expected growth and tap into its potential.
  • With the growing number of surgical procedures worldwide, driven by factors such as increasing awareness and patient affordability for plastic or reconstructive surgeries, the demand for general surgery devices is expected to rise.
  • This investment trend creates a conducive environment for the growth of the general surgery devices market.

Global Medical Plastics Market Report 2023: Sector is Expected to Reach $54.28 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 4, 2023

During the forecasted period of 2023-2028, polypropylene is the fastest growing segment in medical plastics.

Key Points: 
  • During the forecasted period of 2023-2028, polypropylene is the fastest growing segment in medical plastics.
  • By Application: The report provides the medical plastics market analysis based on application: Medical Disposals, Drugs Packaging, Medical Instruments, Prosthetics and Implants and Others.
  • In 2022, North America dominates the global medical plastics market, driven by rise in geriatric population and the increasing demand for home healthcare services.
  • Asia Pacific is anticipated to be the fastest growing region in the medical plastics market.

Intracardiac Echocardiography Devices Market size to grow by USD 11.5 billion from 2022 to 2030; Increasing number of heart-related medical conditions and treatments to boost the market growth - Facts & Factor

Retrieved on: 
Wednesday, June 28, 2023

Global Intracardiac Echocardiography Devices Market: Growth Drivers

Key Points: 
  • Global Intracardiac Echocardiography Devices Market: Growth Drivers
    Increasing number of heart-related medical conditions and treatments to propel market growth.
  • The global intracardiac echocardiography devices market is projected to grow owing to the increasing number of patients suffering from heart-related conditions and their subsequent treatment.
  • Most traditional tools like transoesophageal echocardiography (TEE) are used to prepare for and act as guiding tools during interventional treatment.
  • Global Intracardiac Echocardiography Devices Market: Segmentation
    The global intracardiac echocardiography devices market is segmented based on end-user, application, and region.